Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

IMMUNE SYSTEM AND CVD IN 2018

Targeting inflammation in CVD: advances and challenges

Considerable evidence supports a role for low-grade chronic inflammation in the atherothrombotic process, from plaque initiation to acute plaque rupture preceding myocardial infarction. Publications in 2018 revealed both the promise and challenges of targeting inflammation to treat atherosclerotic cardiovascular disease and highlighted the importance of understanding the mechanistic diversity of inflammatory pathways contributing to atherosclerosis.

Key advances

  • Selective neutralization of the cytokine IL-1β reduces cardiovascular disease events, particularly in individuals who achieved the highest reduction in inflammation as measured by high-sensitivity C-reactive protein (hsCRP) levels1.

  • Low-dose methotrexate does not protect against cardiovascular disease events and, interestingly, also does not reduce IL-1β, IL-6 or hsCRP levels in high-risk patients2.

  • Studies in mice indicate that a high-cholesterol diet can induce long-term reprogramming of haematopoietic reservoirs or ‘innate immune training’ to set the stage for higher inflammation via a mechanism involving IL-1β (ref.3).

  • Inflammation remains an important risk factor after levels of LDL cholesterol have been aggressively reduced, as is now possible with PCSK9 inhibitors in combination with other lipid-lowering therapies4.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119–1131 (2017).

    CAS  Article  Google Scholar 

  2. 2.

    Ridker, P. M. et al. Low-dose methotrexate for the prevention of atherosclerotic events. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1809798 (2018).

    Article  PubMed  Google Scholar 

  3. 3.

    Christ, A. et al. Western diet triggers NLRP3-dependent innate immune reprogramming. Cell 172, 162–175 (2018).

    CAS  Article  Google Scholar 

  4. 4.

    Pradhan, A. D. et al. Residual inflammatory risk on treatment with PCSK9 inhibition and statin therapy. Circulation 138, 141–149 (2018).

    CAS  Article  Google Scholar 

  5. 5.

    Grebe, A., Hoss, F. & Latz, E. NLRP3 inflammasome and the IL-1 pathway in atherosclerosis. Circ. Res. 122, 1722–1740 (2018).

    CAS  Article  Google Scholar 

  6. 6.

    Ridker, P. M. et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet 391, 319–328 (2018).

    CAS  Article  Google Scholar 

  7. 7.

    O’Donoghue, M. L. et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA 312, 1006–1015 (2014).

    Article  Google Scholar 

  8. 8.

    O’Donoghue, M. L. et al. Effect of losmapimod on cardiovascular outcomes in patients hospitalized with acute myocardial infarction: a randomized clinical trial. JAMA 315, 1591–1599 (2016).

    Article  Google Scholar 

  9. 9.

    IL6R Genetics Consortium Emerging Risk Factors Collaboration. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 379, 1205–1213 (2012).

    Article  Google Scholar 

Download references

Acknowledgements

K.J.M.’s work is supported by the NIH (grants R35HL135799 and P01HL131478).

Author information

Affiliations

Authors

Corresponding author

Correspondence to Kathryn J. Moore.

Ethics declarations

Competing interests

The author declares no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Moore, K.J. Targeting inflammation in CVD: advances and challenges. Nat Rev Cardiol 16, 74–75 (2019). https://doi.org/10.1038/s41569-018-0144-3

Download citation

Search

Quick links